Analysts forecast that Chimerix, Inc. (NASDAQ:CMRX) will report ($0.46) earnings per share for the current quarter, Zacks reports. Three analysts have made estimates for Chimerix’s earnings, with the highest EPS estimate coming in at ($0.38) and the lowest estimate coming in at ($0.54). Chimerix reported earnings per share of ($0.37) during the same quarter last year, which suggests a negative year-over-year growth rate of 24.3%. The firm is scheduled to report its next quarterly earnings results on Monday, November 6th.
On average, analysts expect that Chimerix will report full year earnings of ($1.75) per share for the current financial year, with EPS estimates ranging from ($1.99) to ($1.55). For the next financial year, analysts forecast that the firm will post earnings of ($1.83) per share, with EPS estimates ranging from ($2.46) to ($1.49). Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research firms that follow Chimerix.
Chimerix (NASDAQ:CMRX) last announced its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.41) by $0.05. Chimerix had a negative return on equity of 24.07% and a negative net margin of 1,221.34%. The company had revenue of $0.68 million during the quarter, compared to analyst estimates of $1.28 million.
Several equities research analysts have commented on the company. Zacks Investment Research upgraded Chimerix from a “sell” rating to a “hold” rating in a research note on Monday, July 17th. FBR & Co reiterated a “hold” rating and set a $7.00 price objective on shares of Chimerix in a research note on Monday, May 1st. Finally, Cowen and Company reiterated a “hold” rating and set a $6.00 price objective on shares of Chimerix in a research note on Friday, April 28th. Four equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company. Chimerix presently has an average rating of “Hold” and an average price target of $7.55.
Shares of Chimerix (CMRX) traded down 4.87% during trading on Friday, reaching $4.69. The company had a trading volume of 153,757 shares. The stock’s 50-day moving average price is $5.20 and its 200-day moving average price is $5.44. Chimerix has a 52 week low of $3.66 and a 52 week high of $6.64. The company’s market capitalization is $218.79 million.
Large investors have recently bought and sold shares of the company. Victory Capital Management Inc. raised its stake in Chimerix by 88.7% in the second quarter. Victory Capital Management Inc. now owns 229,544 shares of the biopharmaceutical company’s stock valued at $1,251,000 after buying an additional 107,900 shares during the period. Bank of New York Mellon Corp raised its stake in Chimerix by 3.4% in the second quarter. Bank of New York Mellon Corp now owns 253,367 shares of the biopharmaceutical company’s stock valued at $1,381,000 after buying an additional 8,287 shares during the period. Alps Advisors Inc. raised its stake in Chimerix by 5.5% in the second quarter. Alps Advisors Inc. now owns 42,023 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 2,178 shares during the period. State of Wisconsin Investment Board purchased a new stake in Chimerix during the second quarter valued at approximately $185,000. Finally, Rhumbline Advisers raised its stake in Chimerix by 7.3% in the second quarter. Rhumbline Advisers now owns 48,541 shares of the biopharmaceutical company’s stock valued at $265,000 after buying an additional 3,300 shares during the period. Institutional investors own 65.63% of the company’s stock.
WARNING: This article was posted by BBNS and is the sole property of of BBNS. If you are viewing this article on another website, it was copied illegally and reposted in violation of U.S. & international trademark and copyright legislation. The original version of this article can be accessed at https://baseballnewssource.com/markets/zacks-brokerages-anticipate-chimerix-inc-cmrx-to-announce-0-46-earnings-per-share-updated/1409552.html.
Chimerix Company Profile
Chimerix, Inc is a biotechnology company. The Company is focused on discovering, developing and commercializing medicines that address unmet medical needs. Its lead compound, brincidofovir, is in development as an oral and intravenous (IV) formulation for the prevention and treatment of deoxyribonucleic acid (DNA) viruses, including smallpox, adenoviruses (AdV), and the human herpesviruses.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Chimerix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chimerix Inc. and related companies with our FREE daily email newsletter.